Derma Science (fka )

[BioSpecialist]

MAJOR NEWS COMING WITHIN 2 WEEKS .MARKET CAP OF 46 MILLION IS A BIG JOKE .


What's Making News At Derma Sciences?
1/26/2011 5:47 AM ET


(RTTNews) - Shares of Derma Sciences Inc. (DSCI: News ), a medical device / pharmaceutical company focused on wound care, have gained over 50 percent in the last five days as investors eye a couple of near-term catalysts.

The company is developing a drug for wound healing and scar reduction - DSC127, which is under a phase II study on diabetic foot ulcer healing. The phase 1 trial with DSC127 was successfully completed in 2007, and the initial key efficacy results from the phase II trial are expected by the end of this month.

In animal studies, DSC127 has shown to be significantly more effective than Johnson & Johnson's Regranex, the only FDA-approved drug for wound healing.

The total market for accelerated healing and scar reduction drug is estimated at $30 billion and DSC127 has blockbuster potential, according to Derma Sciences. Regranex, which bears a black box warning as it is linked to an increased risk of cancer death, has annual sales of $100 million.

The company will be evaluating future development and partnering opportunities for DSC127 after reporting the top line phase II results. Derma Sciences was also awarded $244,479 from the U.S. government under the Patient Protection and Affordable Care Act related to the development of DSC127.

Derma Sciences, which is focused on wound care products, has three primary business segments - Advanced Wound Care, Basic Wound Care and Drug Development.

The Advanced Wound Care segment includes proprietary dressings like MEDIHONEY, BIOGUARD, XTRASORB, MedEfficiency and ALGICELL. This is a high-growth, high-margins segment. Last July, the company submitted a 510(k) application to the FDA for MEDIHONEY Gel wound & burn dressing and is awaiting the regulatory agency's decision.

The Basic Wound Care segment is the company's core business, generating over 80 percent of current total revenue. This segment includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products.

For the nine months ended September 30, 2010 net sales were up 18 percent to $41.17 million. Net loss for the period widened to $1.97 million or $0.31 per share from $1.18 million or $0.23 per share in 2009. At September 30, 2010, the company had cash and cash equivalents of $409,505 compared to $243,524 in December 31, 2009.

DSCI underwent a 1-for-8 reverse split, which became effective on February 1, 2010. The stock, which has thus far hit a 52-week low of $0.73 and a 52-week high of $9.00, closed Tuesday's trading at $6.98, up 5.28 percent.

[BioSpecialist]

Jump to 12-15$ Coming

FDA approval and Blockbuster PII data coming within 2-3 Weeks.gl

[BioSpecialist]

Great Article out ...This unknown gem is still wayyyy Undervalued .Market Cap of $ 45 M is a big joke for this great Company .

http://www.rttnews.com/Content/TopStories.aspx?Id=1535906


What's Making News At Derma Sciences?
1/26/2011 5:47 AM ET

(RTTNews) - Shares of Derma Sciences Inc. (DSCI: News ), a medical device / pharmaceutical company focused on wound care, have gained over 50 percent in the last five days as investors eye a couple of near-term catalysts.

The company is developing a drug for wound healing and scar reduction - DSC127, which is under a phase II study on diabetic foot ulcer healing. The phase 1 trial with DSC127 was successfully completed in 2007, and the initial key efficacy results from the phase II trial are expected by the end of this month.

In animal studies, DSC127 has shown to be significantly more effective than Johnson & Johnson's Regranex, the only FDA-approved drug for wound healing.

The total market for accelerated healing and scar reduction drug is estimated at $30 billion and DSC127 has blockbuster potential, according to Derma Sciences. Regranex, which bears a black box warning as it is linked to an increased risk of cancer death, has annual sales of $100 million.

The company will be evaluating future development and partnering opportunities for DSC127 after reporting the top line phase II results. Derma Sciences was also awarded $244,479 from the U.S. government under the Patient Protection and Affordable Care Act related to the development of DSC127.

Derma Sciences, which is focused on wound care products, has three primary business segments - Advanced Wound Care, Basic Wound Care and Drug Development.

The Advanced Wound Care segment includes proprietary dressings like MEDIHONEY, BIOGUARD, XTRASORB, MedEfficiency and ALGICELL. This is a high-growth, high-margins segment. Last July, the company submitted a 510(k) application to the FDA for MEDIHONEY Gel wound & burn dressing and is awaiting the regulatory agency's decision.

The Basic Wound Care segment is the company's core business, generating over 80 percent of current total revenue. This segment includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products.

For the nine months ended September 30, 2010 net sales were up 18 percent to $41.17 million. Net loss for the period widened to $1.97 million or $0.31 per share from $1.18 million or $0.23 per share in 2009. At September 30, 2010, the company had cash and cash equivalents of $409,505 compared to $243,524 in December 31, 2009.

DSCI underwent a 1-for-8 reverse split, which became effective on February 1, 2010. The stock, which has thus far hit a 52-week low of $0.73 and a 52-week high of $9.00, closed Tuesday's trading at $6.98, up 5.28 percent.

[BioSpecialist]

Rallyyyyy continues

Derma is still wayyy undervalued with 2 approvals around the corner and a blockbuster in pipeline.

Market cap of 44 mil is a joke .

[BioSpecialist]

This very low float GOLDMINE could move to over 15$ in no time .DSCI is still under Radar,the highest Volume in the history of this stock is only 120K means once investors discover this stock it will move up at the speed of light with 1.5-2 Mil shares on the float .A Partnering for Blockbuster candidate DSC127 could bring huge upfront cash payment which could be much higher than current Market Cap (see post below) .DID YOU REALISE THE FANTASTIC POTENTIAL IN DSCI ??


A lot of MAJOR news coming very soon to push this GOLDMINE to ALL TIME HIGHS .


Market Cap: 34.6 MIL$
Price: 5.28 $

Shares Out: 6.5 MIL // 3 MIL Shares held by Insiders

Short Data : Only 3154 Shares


Upcoming Milestones for 1Q 2011 (New dates below are from the Company ,I got a response yesterday from IR )
http://www.wsw.com/webcast/maxim3/dsci/2__Slide21.JPG

Phase 2 results for Blockbuster Candidate DSC127 this Week or first Week in Feb 2011

Expect FDA 510k Clearance for Medihoney gel 4Q10 = VERY SOON

Submit another 510K Application to FDA for Medihoney Hydro in Jan or early Feb 2011

PartnerShip with upfront cash payment for Potential Blockbuster DSC127 2Q 2011

**************************************************************

A MUST READ ..
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208

KEY PRODUCT UNDER DEVELOPMENT

DSDSC127 (angiotensin analog)

Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.

* "Blockbuster" potential - with applications in the following markets:

o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year

*************************************************************


Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.


**************************************************************


Watch Videos about their great Products !
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10309

[BioSpecialist]

RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYY

Still time to get in cheap

[BioSpecialist]

Some infos about this goldmine

DSC127 PhaseII results coming in a few days .DSC127 has Blockbuster Potential .FDA approval for Medhoney is on the way too .Derma Science has really Multibagger Potential everyone who did his homework will realise this .Do you know what will happen with this very low float stock on FDA Approval or Phase 2 results ??BOOOOOOOOOOOOOOOOOOOOOM is the answer.
My advice is Buy with both hands before the investors discover this stock .


http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208


CORPORATE OVERVIEW
Derma Sciences is a specialty medical device/pharmaceutical company dedicated to manufacturing, marketing, and selling a broad base of wound care products. The company focuses on three primary areas:

1. Advanced Wound Care - Several newly-launched proprietary dressings along with a full line of products for chronic wounds and burns. Approximately 17% of current total revenue, expecting to grow to 28% of total revenue in 2010. This is our high-growth, high-margins area of concentration.
2. Basic Wound Care - Includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products. This is Derma's core business. Currently generating over 80% of current total revenue.
3. Drug Development - Drug candidate DSC127 is in a Phase II study on Diabetic Foot Ulcer healing. Enrollment is expected to be completed within Q3 2010, with initial key efficacy results to be reported towards the end of Q4 2010.

Derma Sciences' products are marketed to wound care centers, long-term care facilities, hospitals, physicians' offices, clinics, home health care agencies and other health care institutions, as well as pharmacies on the retail side of the business.

INVESTMENT HIGHLIGHTS

* Robust product licensing and development history
o 5 novel, advanced wound care products successfully launched in the past 3 years, generating $6 million in sales in 2009 and expected to grow to $15M in sales in 2010
* Powerful growth engine: Advanced Wound Care
o Advanced Wound Care sales force in US will double in 2010 (from 10 to 20)
o Global market for Advanced Wound Care products totals almost $5 billion and is growing approximately 10% annually
* DSC127 has blockbuster potential
o Total market for accelerated healing and scar reduction drug estimated at $30 billion
o Phase II trial results expected in 4Q10.
* Recently acquired perpetual, global rights to key brand, MEDIHONEY
o Acquisition is a catalyst for company's international expansion
* Strong cash flow core business with good growth potential
o Positive cash flow will fund growth initiatives
* DSCI stock is undervalued
o Current market cap is substantially less than 2009 sales

KEY PRODUCT UNDER DEVELOPMENT

DSDSC127 (angiotensin analog)
Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.

* "Blockbuster" potential - with applications in the following markets:
o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year

[BioSpecialist]

BREAKOUT COMING FOLKS...

Get on board NOW before the stock gets Discovered.DONT MISS THE NEXT JAZZ !


We could see 25-30$ quckily with only 1-2 million shares on the Float.


Derma Science (DSCI)

Market Cap: 32 Mil
Price: 4.89

Shares Outstanding: 6.5 Mil.....(Held by Insiders: 3 Mil )


In early 3Q10 the Company submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for MEDIHONEY® Gel Wound & Burn Dressing. This latest MEDIHONEY line extension is dispensed from a tube and is comprised of Active Manuka (Leptospermum) Honey blended with gelling agents. It is intended for use in hard-to-dress areas and wounds. Expect FDA 510k Clearance for Medihoney gel 4Q10


Derma Sciences expects to announce top-line efficacy results of its Phase 2 clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of January 2011.

[BioSpecialist]

FDA Pick with 300-500% upside Potential !!!

This 100% real unknown Stock is awaiting FDA approval and Major Phase II Results for their Flagship product DSC127 in 1Q 2011 .DSCI is one of the most undervalued stock ever i see in the Biotech Space !!! The real Value is between 20- 30$ per Share !!

ITS A WIN WIN SITUATION FROM THIS LEVEL .DO YOUR RESEARCH AND REALISE THE MEGA POTENTIAL !GL


RODMAN HAS A OUTPERFORM RATING FOR DSCI :
Derma Sciences, Inc. DSCI Rodman & Renshaw Mkt Outperform $13


Derma Science (DSCI)

Market Cap : 30.5 M
Share Price : 4.65

Annual Revenue : 55 M


SHARE STATISTIC :

Shares Out : 6.5 M
Float: 3.2 M
Held by Insiders : 3 M



ENOUGH CASH :

As of September 30, 2010, working capital was $9,587,806, and cash and cash equivalents were $409,505. Line of credit borrowing was $3,658,625 at quarter end with approximately $1,200,000 of additional availability.



TWO APPROVALS ON THE WAY (See Slide presentation below for more Infos) :

We made progress with our two 510(k) submissions to the U.S. Food and Drug Administration for new MEDIHONEY line extensions and are looking forward to bringing those products to market in the near future.



PHASE II RESULTS FOR MAJOR DRUG THIS MONTH :

"We were very pleased to complete patient enrollment at the end of September in our Phase II trial with DSC127 in diabetic wound healing. We anticipate reporting top-line efficacy data between late December and mid January. Should the trial be successful, we are evaluating several options, including bringing on a partner.


Check out this Slide Presentation :

http://www.wsw.com/webcast/maxim3/dsci/2__Slide9.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide21.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide15.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide16.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide4.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide6.JPG

http://www.wsw.com/webcast/maxim3/dsci/2__Slide22.JPG